- Home
- EQ vs BTMD Comparison
EQ vs BTMD Comparison
Compare EQ & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- BTMD
- Stock Information
- Founded
- EQ 2017
- BTMD 2012
- Country
- EQ United States
- BTMD United States
- Employees
- EQ N/A
- BTMD N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- EQ Health Care
- BTMD Health Care
- Exchange
- EQ Nasdaq
- BTMD Nasdaq
- Market Cap
- EQ 85.1M
- BTMD 90.0M
- IPO Year
- EQ 2018
- BTMD N/A
- Fundamental
- Price
- EQ $1.39
- BTMD $2.87
- Analyst Decision
- EQ Hold
- BTMD Buy
- Analyst Count
- EQ 2
- BTMD 2
- Target Price
- EQ $1.00
- BTMD $6.00
- AVG Volume (30 Days)
- EQ 489.3K
- BTMD 105.6K
- Earning Date
- EQ 11-11-2025
- BTMD 11-05-2025
- Dividend Yield
- EQ N/A
- BTMD N/A
- EPS Growth
- EQ N/A
- BTMD 642.53
- EPS
- EQ N/A
- BTMD 0.88
- Revenue
- EQ $16,553,000.00
- BTMD $199,073,000.00
- Revenue This Year
- EQ N/A
- BTMD N/A
- Revenue Next Year
- EQ N/A
- BTMD $4.85
- P/E Ratio
- EQ N/A
- BTMD $3.26
- Revenue Growth
- EQ N/A
- BTMD 6.32
- 52 Week Low
- EQ $0.27
- BTMD $2.65
- 52 Week High
- EQ $2.35
- BTMD $6.98
- Technical
- Relative Strength Index (RSI)
- EQ 48.48
- BTMD 46.36
- Support Level
- EQ $1.31
- BTMD $2.78
- Resistance Level
- EQ $1.58
- BTMD $2.90
- Average True Range (ATR)
- EQ 0.13
- BTMD 0.14
- MACD
- EQ 0.01
- BTMD 0.01
- Stochastic Oscillator
- EQ 48.64
- BTMD 34.43
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.